{"classes":[{"categories":[{"measurements":[{"groupId":"OG000","spread":"0.544","value":"339"}]}],"denoms":[{"counts":[{"groupId":"OG000","value":"52"}],"units":"Participants"}],"title":"Week 1 (Study Day 1)"},{"categories":[{"measurements":[{"groupId":"OG000","spread":"0.959","value":"343"}]}],"denoms":[{"counts":[{"groupId":"OG000","value":"30"}],"units":"Participants"}],"title":"Week 9 (Study Day 57)"},{"categories":[{"measurements":[{"groupId":"OG000","spread":"0.649","value":"304"}]}],"denoms":[{"counts":[{"groupId":"OG000","value":"20"}],"units":"Participants"}],"title":"Week 17 (Study Day 113)"}],"denoms":[{"counts":[{"groupId":"OG000","value":"52"}],"units":"Participants"}],"description":"Cmax is maximum observed plasma concentration. Cmax of MEK162 was observed directly from data.","dispersionType":"Geometric Coefficient of Variation","groups":[{"description":"Participants received an oral dose of 45 milligram (mg) of MEK162 tablets (3 tablets of 15 mg) twice daily for each 28-day treatment cycle until disease progression, withdrawal of consent, initiation of subsequent anticancer therapy, lost to follow-up or death, whichever occurred first. Participants were followed up to 30 days after last dose of study intervention.","id":"OG000","title":"MEK162"}],"paramType":"GEOMETRIC_MEAN","populationDescription":"The PK set consisted of all participants who received at least 1 dose of MEK162 and had at least 1 PK blood collection with associated bioanalytical results.","reportingStatus":"POSTED","timeFrame":"2 hours ± 10 minutes postdose on Study Days 1, 57, and 113.","title":"Maximum Observed Plasma Concentration (Cmax) of MEK162","type":"SECONDARY","unitOfMeasure":"ng/mL"}